N@N

AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL), Down By 12.26% ($2.87) From $23.410 After BUYINS.NET Report Predicted Weakness Afte

^{Published on 2011-04-06 11:01:09 - WOPRAI}
 

April 6, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, February 9th 2011 stating that AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=auxl&id=145807

At the time this story was written, AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL) is Down By 12.26% ($2.87) From $23.410 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL) - Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, rheumatologists, and orthopedic, general, and plastic surgeons primarily in the United States. The company markets Testim, a topical 1% testosterone gel for the treatment of hypogonadism; and XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of Dupuytrens contracture. The company also develops XIAFLEX, which is in Phase II clinical trials for the treatment of Peyronies disease and Adhesive Capsulitis. In addition, its product pipeline includes AA4010 that is in Phase I clinical trials for the treatment for overactive bladder using its transmucosal film delivery system; and A Fentanyl, a pain product, which is under Phase I clinical trials. In addition, the company has rights to develop other compounds for the treatment of pain using its transmucosal film delivery system; and other products for the treatment of urologic disease and hormone replacement using its transmucosal film technology. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. AUXILIUM PHARMACEUTICALS INC (NASDAQ:AUXL) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net